@article{e3fa4e32bba443e79a8e1c43e7f6b536,
title = "Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study",
abstract = "Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome inMZL and identifies a high-risk population. {\textcopyright} 2019 by The American Society of Hematology.",
keywords = "albumin, bendamustine, beta 2 microglobulin, cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, fludarabine, hemoglobin, lactate dehydrogenase, adult, albumin blood level, Article, autologous stem cell transplantation, cancer chemotherapy, cancer immunotherapy, cancer radiotherapy, cause of death, cause specific survival, cohort analysis, disease duration, disease exacerbation, Follicular Lymphoma International Prognostic Index, follow up, hemoglobin blood level, high risk population, human, immunochemotherapy, lactate dehydrogenase blood level, lymphocyte count, major clinical study, marginal zone lymphoma, middle aged, observational study, overall survival, platelet count, priority journal, prospective study, survival analysis, systemic therapy, aged, female, male, mortality, pathology, prognosis, time factor, very elderly, Adult, Aged, Aged, 80 and over, Disease Progression, Female, Humans, Lymphoma, B-Cell, Marginal Zone, Male, Middle Aged, Prognosis, Prospective Studies, Survival Analysis, Time Factors",
author = "S. Luminari and M. Merli and S. Rattotti and V. Tarantino and L. Marcheselli and F. Cavallo and M. Varettoni and B. Bianchi and F. Merli and A. Tedeschi and G. Cabras and F. Re and C. Visco and M.T. Delamain and E. Cencini and M. Spina and S. Ferrero and A. Ferrari and M. Deodato and D. Mannina and O. Annibali and A. Rago and L. Orsucci and I. Defrancesco and M. Frigeni and M. Cesaretti and L. Arcaini",
note = "Cited By :2 Export Date: 25 February 2020 CODEN: BLOOA Correspondence Address: Luminari, S.; Programma di Ricerca Clinica Oncoematologica, IRCCS, Universit{\`a} DiModena e Reggio Emilia, Viale Risorgimento 80, Italy; email: stefano.luminari@unimore.it Chemicals/CAS: bendamustine, 16506-27-7, 3543-75-7; beta 2 microglobulin, 9066-69-7; fludarabine, 21679-14-1; hemoglobin, 9008-02-0; lactate dehydrogenase, 9001-60-9 Funding details: Fondazione IRCCS Policlinico San Matteo Funding details: Universit{\`a} degli Studi dell'Insubria Funding details: Universit{\`a} degli Studi di Pavia Funding details: Universit{\`a} degli Studi di Torino, UNITO Funding details: Universit{\`a} Degli Studi di Modena e Reggio Emila, UNIMORE Funding details: American Ornithologists' Union, AOU Funding details: Universit{\`a} degli Studi di Verona Funding details: National Cancer Institute, NCI Funding text 1: 1Division of Hematology, Azienda Unit{\`a} Sanitaria Locale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Reggio Emilia, Reggio Emilia, Italy; 2Surgical, Medical and Dental Department of Morphological Sciences related to the Transplant, Oncology and Regenerative Medicine Department, University of Modena and Reggio Emilia, Modena, Italy; 3Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi–Azienda Socio-Sanitaria Territoriale Sette Laghi, University of Insubria, Varese, Italy; 4Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 5PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy; 6Lymphoma Unit, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy; 7Fondazione Italiana Linfomi, Modena, Italy;8Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy; 9Division of Hematology 1, Azienda Ospedaliera Universitaria (AOU) Citt{\`a} della Salute e della Scienza di Torino, Turin, Italy; 10Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy; 11Division of Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy; 12Division of Hematology, Azienda Ospedaliero–Universitaria di Parma, Parma, Italy; 13Section of Hematology, Department of Medicine, University of Verona, Verona, Italy; 14Center of Hematology and Hemotherapy, Department of Internal Medicine, Faculty of Medicine, State University of Campinas, Campinas, Brazil; 15Division of Hematology, Department of Oncology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy; 16Division of Medical Oncology A, National Cancer Institute, Aviano, Italy; 17Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy; 18Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, University Campus Bio-Medico, Rome, Italy; 19Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy; 20Division of Hematology 2, AOU Citt{\`a} della Salute e della Scienza di Torino, Turin, Italy; and 21Department of Molecular Medicine, University of Pavia, Pavia, Italy References: Swerdlow, S.H., Campo, E., Pileri, S.A., The 2016 revision of the World Health Organization classification of lymphoid neoplasms (2016) Blood, 127 (20), pp. 2375-2390; Thieblemont, C., Cascione, L., Conconi, A., A MALT lymphoma prognostic index (2017) Blood, 130 (12), pp. 1409-1417; Arcaini, L., Rattotti, S., Gotti, M., Luminari, S., Prognostic assessment in patients with indolent B-cell lymphomas (2012) ScientificWorldJournal, 2012, p. 107892; Montalb{\'a}n, C., Abraira, V., Arcaini, L., Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases (2012) Br J Haematol, 159 (2), pp. 164-171. , [published correction appears in Br J Haematol 2013;162(6):864]. Splenic Marginal Zone Lymphoma Study Group; Casulo, C., Byrtek, M., Dawson, K.L., Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the national LymphoCare study (2015) J Clin Oncol, 33 (23), pp. 2516-2522; Maurer, M.J., Ellin, F., Srour, L., International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma (2017) J Clin Oncol, 35 (36), pp. 4019-4026; Maurer, M.J., Ghesqui{\`e}res, H., Jais, J.P., Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy (2014) J Clin Oncol, 32 (10), pp. 1066-1073; Visco, C., Tisi, M.C., Evangelista, A., Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death (2019) Br J Haematol, 185 (5), pp. 940-944. , Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network; Tracy, S.I., Larson, M.C., Feldman, A.L., The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas (2019) Am J Hematol, 94 (6), pp. 658-666; Cheson, B.D., Fisher, R.I., Barrington, S.F., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification (2014) J Clin Oncol, 32 (27), pp. 3059-3068. , United Kingdom National Cancer Research Institute; Freeman, C.L., Savage, K.J., Villa, D., Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: Prognosis among patients with progression of disease by 24months (POD24) is poor with majority having transformed lymphoma [abstract] (2018) Blood, 132. , Abstract 2873; Conconi, A., Franceschetti, S., Aprile Von Hohenstaufen, K., Histologic transformation in marginal zone lymphomas (2015) Ann Oncol, 26 (11), pp. 2329-2335; Alderuccio, J.P., Zhao, W., Desai, A., Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution J Clin Oncol, , [published online ahead of print 12 October 2018]; Casulo, C., Friedberg, J.W., Ahn, K.W., Autologous transplantation in follicular lymphoma with early therapy failure: A national LymphoCare study and Center for International Blood and Marrow Transplant research analysis (2018) Biol Blood Marrow Transplant, 24 (6), pp. 1163-1171; Jurinovic, V., Metzner, B., Pfreundschuh, M., Autologous stem cell transplantation for patients with early progression of follicular lymphoma: A follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group (2018) Biol Blood Marrow Transplant, 24 (6), pp. 1172-1179",
year = "2019",
month = sep,
day = "5",
doi = "10.1182/blood.2019001088",
language = "English",
volume = "134",
pages = "798--801",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",
}